IMU Biosciences Ltd, a two-year old UK company, has raised £11.5 million from private investors to create a map of the human immune system using artificial intelligence. The goal is be able to monitor the presence of immune disorders early and guide the development of targeted drugs, also known as precision medicines. The Series A financing was announced on 24 January and led by Moulton Ventures Plc. It also included LifeX Ventures and several individuals.
